Free tool
FAERS Monitor: Bupivacaine Hydrochloride
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022046 or its brand name (Bupivacaine Hydrochloride, Bupivacaine Hydrochloride, Epinephrine Bitartrate). Reports on generic versions are filed under their own applications.
Reports
2,117
Serious
1,388
66% of reports
Hospitalization
628
Death reported
225
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective581
- maternal exposure during pregnancy197
- anaesthetic complication196
- off label use165
- hypoaesthesia144
- hypotension125
- condition aggravated123
- dyspnoea117
- hypertension117
- headache112
- fatigue99
- dizziness94
- helicobacter infection91
- vomiting90
- fibromyalgia87
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2005 | 3 |
| 2006 | 13 |
| 2007 | 7 |
| 2008 | 9 |
| 2009 | 24 |
| 2010 | 32 |
| 2011 | 10 |
| 2012 | 21 |
| 2013 | 26 |
| 2014 | 21 |
| 2015 | 94 |
| 2016 | 280 |
| 2017 | 32 |
| 2018 | 65 |
| 2019 | 69 |
| 2020 | 94 |
| 2021 | 135 |
| 2022 | 241 |
| 2023 | 182 |
| 2024 | 270 |
| 2025 | 282 |
| 2026 | 207 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,042 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| anaesthetic complicationSignal | 196 | 782.1 | 680.6 | 141,052 |
| helicobacter infectionSignal | 91 | 88.7 | 72.5 | 7,740 |
| fibromyalgiaSignal | 87 | 35.7 | 29.0 | 2,891 |
| maternal exposure during pregnancySignal | 197 | 22.0 | 19.3 | 3,937 |
| hypoaesthesiaSignal | 144 | 9.6 | 8.2 | 1,103 |
| hypotensionSignal | 125 | 6.2 | 5.2 | 544 |
| hypertensionSignal | 117 | 5.5 | 4.6 | 429 |
| drug ineffectiveSignal | 581 | 4.4 | 4.1 | 1,613 |
| condition aggravatedSignal | 123 | 4.0 | 3.4 | 280 |
| dyspnoeaSignal | 117 | 2.1 | 1.7 | 64 |
| vomiting | 90 | 1.9 | 1.6 | 38 |
| dizziness | 94 | 1.9 | 1.5 | 38 |
| off label use | 165 | 1.9 | 1.6 | 69 |
| headache | 112 | 1.8 | 1.5 | 38 |
| fatigue | 99 | 1.3 | 1.0 | 5 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.